JP2014529395A - ボツリヌス神経毒のタンパク質分解的切断の改変 - Google Patents

ボツリヌス神経毒のタンパク質分解的切断の改変 Download PDF

Info

Publication number
JP2014529395A
JP2014529395A JP2014523291A JP2014523291A JP2014529395A JP 2014529395 A JP2014529395 A JP 2014529395A JP 2014523291 A JP2014523291 A JP 2014523291A JP 2014523291 A JP2014523291 A JP 2014523291A JP 2014529395 A JP2014529395 A JP 2014529395A
Authority
JP
Japan
Prior art keywords
dystonia
light chain
bont
calpain
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014529395A5 (enExample
Inventor
フレーヴェルト，ユルゲン
Original Assignee
メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー
メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー, メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー filed Critical メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー
Publication of JP2014529395A publication Critical patent/JP2014529395A/ja
Publication of JP2014529395A5 publication Critical patent/JP2014529395A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
JP2014523291A 2011-08-04 2012-07-26 ボツリヌス神経毒のタンパク質分解的切断の改変 Pending JP2014529395A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161574596P 2011-08-04 2011-08-04
EP11176531.9 2011-08-04
EP11176531 2011-08-04
US61/574,596 2011-08-04

Publications (2)

Publication Number Publication Date
JP2014529395A true JP2014529395A (ja) 2014-11-13
JP2014529395A5 JP2014529395A5 (enExample) 2016-07-28

Family

ID=47628649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523291A Pending JP2014529395A (ja) 2011-08-04 2012-07-26 ボツリヌス神経毒のタンパク質分解的切断の改変

Country Status (6)

Country Link
US (1) US20140170133A1 (enExample)
EP (1) EP2739297A1 (enExample)
JP (1) JP2014529395A (enExample)
AU (1) AU2012292163A1 (enExample)
CA (1) CA2841933A1 (enExample)
WO (1) WO2013017522A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
WO2018081282A1 (en) * 2016-10-25 2018-05-03 Cellsnap Llc Neurotoxins and uses thereof
EP3335719A1 (en) * 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
CN118126143B (zh) * 2024-03-14 2025-06-24 河北平朴生物科技合伙企业(有限合伙) 一种a型肉毒毒素的突变体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517627A (ja) * 2000-07-21 2005-06-16 アラーガン、インコーポレイテッド ロイシンベースモチーフおよびクロストリジウム神経毒
WO2010094905A1 (en) * 2009-02-23 2010-08-26 Syntaxin Limited Modified non-cytotoxic proteases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6943555B2 (en) * 2002-05-23 2005-09-13 Lockheed Martin Corporation Redundant safety circuit for squib testing
ES2592314T3 (es) * 2008-08-29 2016-11-29 Merz Pharma Gmbh & Co. Kgaa Neurotoxinas clostridiales con persistencia modificada

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517627A (ja) * 2000-07-21 2005-06-16 アラーガン、インコーポレイテッド ロイシンベースモチーフおよびクロストリジウム神経毒
WO2010094905A1 (en) * 2009-02-23 2010-08-26 Syntaxin Limited Modified non-cytotoxic proteases

Also Published As

Publication number Publication date
US20140170133A1 (en) 2014-06-19
CA2841933A1 (en) 2013-02-07
WO2013017522A1 (en) 2013-02-07
EP2739297A1 (en) 2014-06-11
AU2012292163A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
JP4818565B2 (ja) ロイシンベースモチーフおよびクロストリジウム神経毒
EP2449101B1 (en) Neurotoxins exhibiting shortened biological activity
KR100873819B1 (ko) 근육 손상의 처치방법
KR102083373B1 (ko) 단백질 가수분해 처리된 폴리펩티드의 제조방법
AU2009286973B2 (en) Clostridial neurotoxins with altered persistency
US9314514B2 (en) Modified neurotoxins with poly-glycine and uses thereof
US20020086036A1 (en) Methods for treating hyperhidrosis
US8008465B2 (en) Nucleic acids encoding chimera botulinum toxin type E
AU2005205597A1 (en) Chimera botulinum toxin type E
UA129511C2 (uk) СПОСІБ ОДЕРЖАННЯ РОЗЧИННОГО ДВОЛАНЦЮГОВОГО BoNT/A БІЛКА
JPH10500988A (ja) 輸送タンパク質用クロストリジウム属細菌毒素の修飾
KR20220154739A (ko) 상부 얼굴 주름의 치료
TW201718627A (zh) 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
US20040126827A1 (en) Novel proteins within the type E botulinum neurotoxin complex
CA2841933A1 (en) Alteration of proteolytic cleavage of botulinum neurotoxins
KR102565312B1 (ko) 활성화된 클로스트리디움 신경독소의 생산
JP2013538050A (ja) 組換え神経毒ポリペプチドの選択的製造
WO2012041761A2 (en) Botulinum neurotoxin polypeptides exhibiting a prolonged activity
CN119095579A (zh) 上面部纹的治疗
HK40078498A (en) Treatment of upper facial lines
HK1155176A (en) Clostridial neurotoxins with altered persistency
HK1120051A (en) Carrier for targeting nerve cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160309

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171031